鹭燕医药(002788) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥4,188,190,309.50, representing a year-on-year increase of 5.90%[7] - Net profit attributable to shareholders of the listed company was ¥82,519,565.51, up 10.08% compared to the same period last year[7] - Basic earnings per share for the reporting period was ¥0.25, an increase of 8.70% year-on-year[7] - Total operating revenue for the third quarter reached CNY 4,188,190,309.50, an increase from CNY 3,954,712,910.02 in the previous period[46] - Net profit for the quarter was CNY 82,111,449.42, up from CNY 74,567,103.22 year-over-year, representing a growth of approximately 7.3%[48] - The net profit for the period was ¥311,090,759.75, compared to ¥106,342,637.93 in the same period last year, indicating a significant increase[61] - The total profit amounted to ¥310,272,035.69, up from ¥104,005,073.83 in the previous year[59] Assets and Liabilities - Total assets at the end of the reporting period reached ¥8,375,256,952.27, an increase of 11.11% compared to the end of the previous year[7] - The total liabilities increased to CNY 6,011,732,549.66 from CNY 5,649,973,377.86, representing a growth of about 6.4%[40] - Current liabilities rose to CNY 5,864,727,193.84, compared to CNY 5,507,022,117.55, reflecting an increase of about 6.5%[40] - The company reported a total non-current asset value of CNY 1,165,443,250.68, up from CNY 1,120,372,674.75, reflecting a growth of about 4%[43] - The total amount of entrusted financial management is CNY 34,200 million, with no overdue amounts reported[29] - The total cash and cash equivalents at the end of the period were ¥354,059,041.08, an increase from ¥284,247,816.73 at the beginning of the period[65] Cash Flow - The net cash flow from operating activities for the reporting period was -¥238,364,012.10, a decline of 196.60% compared to the previous year[7] - The cash flow from operating activities showed a net outflow of ¥350,694,303.54, an improvement from a net outflow of ¥728,811,581.82 in the previous period[64] - The cash flow from investing activities resulted in a net outflow of ¥75,336,083.40, compared to a net outflow of ¥166,319,314.32 in the same period last year[65] - The cash outflow for purchasing goods and services was 1,829,379,551.19 CNY, down from 1,974,091,131.52 CNY, indicating better cost management[66] Shareholder Information - Net assets attributable to shareholders of the listed company amounted to ¥2,286,670,252.67, reflecting a growth of 27.63% year-on-year[7] - The number of ordinary shareholders at the end of the reporting period was 31,280[11] - The largest shareholder, Xiamen Maidi Technology Co., Ltd., held 35.34% of the shares, totaling 115,506,840 shares[11] Legal and Compliance - The company is involved in a legal dispute regarding a civil lawsuit for RMB 1,000 million in remaining equity transfer payments and RMB 182.50 million in delayed performance fees[18] - The company has initiated litigation to hold the equity transferors and guarantors of its subsidiary accountable for breach of contract, claiming damages of RMB 43.62 million[17] - The company has signed a settlement agreement with multiple parties to prioritize the use of project sales revenue for debt repayment[17] Investment and Projects - The company raised a total of RMB 338,657,765.04 through a rights issue, with a subscription rate of 96.79% for 61,686,296 shares at a price of RMB 5.49 per share[16] - The company has allocated RMB 12,633.36 million for the Fuzhou warehousing center project and RMB 11,008.86 million for the Putian logistics center project[24] - The total committed investment amount for projects is CNY 54,130.05 million, with a total adjusted investment amount of CNY 61,287.99 million, achieving an investment progress of 82.84%[25] Research and Development - Research and development expenses for the quarter were CNY 981,081.10, a decrease from CNY 1,278,053.76 in the previous year[47] - Research and development expenses were CNY 2,742,498.28, down from CNY 3,284,649.64 in the previous year, reflecting a reduction of approximately 16.5%[55] - Research and development expenses remained at ¥0.00, indicating no investment in R&D during this period[59] Financial Management - The company has no idle fundraising temporarily for working capital as of September 30, 2020[27] - The company has not experienced significant changes in its investment projects or any major changes in the feasibility of projects[25] - The company has not undergone an audit for the third-quarter report[78]